Next Article in Journal
A Menthol-Enhanced “Cooling” Energy Gel Does Not Influence Laboratory Time Trial Performance in Trained Runners
Previous Article in Journal
Bibliometric and Visual Analysis of Global Research on Taurine, Creatine, Carnosine, and Anserine with Metabolic Syndrome: From 1992 to 2022
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 15
10.3390/nu15153378
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Amino Acid Catabolism: An Overlooked Area of Metabolism

by
Nimbe Torres
†,
Sandra Tobón-Cornejo
†,
Laura A. Velazquez-Villegas
†,
Lilia G. Noriega
,
Gabriela Alemán-Escondrillas
and
Armando R. Tovar
*
Departamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No 15. Col Belisario Domínguez-Sección XVI, Tlalpan, Mexico City 14080, Mexico
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Nutrients 2023, 15(15), 3378; https://doi.org/10.3390/nu15153378
Submission received: 22 June 2023 / Revised: 14 July 2023 / Accepted: 24 July 2023 / Published: 29 July 2023
(This article belongs to the Section Nutrition and Metabolism)
Browse Figures
Versions Notes

Abstract

:
Amino acids have been extensively studied in nutrition, mainly as key elements for maintaining optimal protein synthesis in the body as well as precursors of various nitrogen-containing compounds. However, it is now known that amino acid catabolism is an important element for the metabolic control of different biological processes, although it is still a developing field to have a deeper understanding of its biological implications. The mechanisms involved in the regulation of amino acid catabolism now include the contribution of the gut microbiota to amino acid oxidation and metabolite generation in the intestine, the molecular mechanisms of transcriptional control, and the participation of specific miRNAs involved in the regulation of amino acid degrading enzymes. In addition, molecules derived from amino acid catabolism play a role in metabolism as they are used in the epigenetic regulation of many genes. Thus, this review aims to examine the mechanisms of amino acid catabolism and to support the idea that this process is associated with the immune response, abnormalities during obesity, in particular insulin resistance, and the regulation of thermogenesis.

Graphical Abstract

1. Introduction

Amino acids are used to synthesize body proteins and serve as precursors of many molecules, including neurotransmitters, hormones, purines, pyrimidines, and some vitamins, among others. Upon fasting or when amino acids are ingested in excess of the amounts required, their catabolism serves as an energy source. When amino acids are used for energy production, they undergo the loss of their amino groups; their remaining carbon skeletons have two primary fates: conversion into glucose through gluconeogenesis or oxidation to synthesize ATP. For this reason, there must be a balance between the synthesis and continuous degradation of proteins in the body to ensure the maintenance of optimally functioning proteins. In the steady state, protein synthesis is equal to degradation, and neither the related transcription of amino acid degrading enzymes nor the metabolites generated from these processes are affected [1]. In addition, when the body protein reserve is altered due to increased protein degradation, as occurs, for instance, in the case of cachexia, vertebrates actively oxidize endogenous amino acids from the turnover of body proteins, similar to when ingested proteins exceed protein requirements (Figure 1A).
The catabolic pathways of most amino acids take place mainly in the liver, according to the large body of evidence reported throughout the development of metabolic biochemistry, with the exception of the branched-chain amino acids (BCAA), leucine, valine, and isoleucine [2]. The α-amino nitrogen atoms removed from amino acids during their oxidative degradation are ultimately excreted in the urine as urea to prevent the potential toxicity of a high amount of circulating ammonium. In the catabolism of most amino acids (Figure 1B), the removal of the α-amino group constitutes the first stage and occurs via two major enzymatic pathways: transamination and oxidative deamination. Then, as a second stage, the carbon skeletons of the amino acids are channeled into the tricarboxylic acid cycle to obtain energy in the form of ATP, and some serve as substrates for the gluconeogenic pathway [3]. However, new studies have shown that hepatic catabolism of amino acids is not their only fate. In other cell types or tissues, the catabolism of some amino acids plays a regulatory role that was not initially recognized. The complexity of the molecular mechanisms, as well as the potential metabolic implications associated with the regulation of amino acid catabolism in different physiological and pathological conditions, have been scarcely reviewed. Thus, this review aims to understand the mechanisms of regulation of amino acid catabolism and to highlight the influence of some metabolites, products of their degradation, on the epigenetic regulation of several genes and the involvement of the intestinal microbiota in amino acid catabolism. Further consequences of alterations in these new mechanisms of amino acid catabolism have implications on the immune response during obesity, type 2 diabetes, and thermogenesis, as will be described.

2. Enterohepatic Axis of Amino Acid Catabolism

After protein digestion, amino acids are absorbed and used not only by intestinal cells but also by the resident bacteria; once they have passed through the gut, a fraction of the amino acids are transferred to the bloodstream to reach the liver [4]. Several studies have shown active amino acid utilization and turnover in the enterohepatic axis, which is key for several physiological processes, including the immune response [5], bacteria metabolism, and generation of end-products, where the intestine and the gut microbiota play an important role [6].

2.1. Protein Hydrolysis and Amino Acid Absorption in the Gut

After passing through the esophagus and gastric lumen, dietary protein is hydrolyzed in the small intestine by the proteases and peptidases, including trypsin, chymotrypsin, or carboxypeptidases released by the pancreas [7]. In the intestinal mucosa, an intense renewal of protein occurs at approximately 50% per day in humans, indicating that amino acids are key effectors of gut protein turnover [8]. Many studies have focused on two amino acids, glutamine and arginine, in protein synthesis; however, amino acid catabolism in the intestine has not been extensively documented [8]. The brush border cells of the intestinal mucosa release some peptidases that are used for protein hydrolysis; these enzymes are more active at neutral to alkaline pH, which is reached in the small intestine, to catalyze the hydrolysis of dietary protein to produce amino acids and peptides that are actively absorbed by the enterocytes [9]. Although the process is quite efficient, some nitrogenated products are not taken up by the small intestine, pass through the ileocecal junction, and can be found in the large intestine [10]. Figure 2A outlines this process of protein digestion and absorption of peptides and amino acids, showing its passage through the gastrointestinal system.

2.2. Amino Acid Catabolism in the Intestine

Amino acids and some peptides found in the intestinal lumen after digestion can be delivered to the portal vein due to the presence of specific transporters known as solute carriers (SCL) in the brush border or apical membrane (SLC1A1, SLC6A19, SLC7A1, SLC38A5, SLC36A1, SLC15A1 transporters), and in the basolateral membrane of the enterocytes (members of the SLC7A family and SCL16A10, SLC38A2 transporters) [11] (Figure 2B). However, a large number of dietary amino acids, particularly BCAA, are partially catabolized in the gut since branched-chain aminotransferase (BCAT), the first enzyme in the degradation of the BCAA leucine, valine, and isoleucine, has been reported to be present in the gut [12]. Almost all dietary glutamate, aspartate, and approximately 30–70% of BCAA, glutamine, proline, lysine, threonine, methionine, and phenylalanine are metabolized in the small intestine of mammals, including humans [13]. These data suggest that several amino acid degrading enzymes (AADEs) are expressed in enterocytes. It has been shown that cells of the small intestinal mucosa express lysine α-ketoglutarate reductase in pigs [14]; methionine transamination [15] and glutamine transaminase K in rats [16]; threonine dehydrogenase in pigs [17]; BCAA transaminase and branched-chain α-keto acid (BCKA) dehydrogenase in humans and pigs [2,18]; and proline oxidase in pigs and rats [19]. Also, several enzymes for arginine and glutamine degradation are present, including arginase II, phosphate-dependent glutaminase (PDG), carbamoylphosphate synthase II (glutamine) (CPS-II), glutamate-oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT), pyrroline-5-carboxylate (P5C) synthase, ornithine aminotransferase (OAT), P5C reductase, ornithine carbamoyltransferase (OCT), carbamoylphosphate synthase I (ammonia) (CPS-I), argininosuccinate synthase (ASS), argininosuccinate lyase (ASL), and ornithine decarboxylase (ODC) [20,21,22].
In the colonic lumen, colonocytes can use glutamine as a fuel substrate and catabolize arginine into ornithine and nitric oxide [23]. The conversion of arginine into ornithine significantly increases its capacity in response to an elevated protein intake, which attenuates the rising ammonia concentration in the blood if the urea cycle requires more ornithine [24].
Nutrients 15 03378 g002 550
Figure 2. Protein hydrolysis, amino acid absorption, and catabolism in the gastrointestinal tract. (A) Upon reaching the stomach, proteins undergo a denaturation process caused by hydrochloric acid and pepsin to generate polypeptides [25]. In the small intestine, proteases and peptidases, released from the pancreas, continue the hydrolyzation of polypeptides, generating smaller peptides and free amino acids. Enterocytes in the small intestine also secrete peptidases that complete the hydrolysis of some peptides. (B) Amino acids are translocated from the intestinal lumen to the circulation by specific amino acid transporters (Solute Carriers Transporters (SLC)), expressed in the apical and basolateral membranes of the enterocytes [11]. (C) The bioavailability of amino acids and (D) protein consumed can generate multiple nitrogen-derived compounds or contribute to the generation of polyamines, nitric oxide, short-chain fatty acids, and ammonia, among others.
Figure 2. Protein hydrolysis, amino acid absorption, and catabolism in the gastrointestinal tract. (A) Upon reaching the stomach, proteins undergo a denaturation process caused by hydrochloric acid and pepsin to generate polypeptides [25]. In the small intestine, proteases and peptidases, released from the pancreas, continue the hydrolyzation of polypeptides, generating smaller peptides and free amino acids. Enterocytes in the small intestine also secrete peptidases that complete the hydrolysis of some peptides. (B) Amino acids are translocated from the intestinal lumen to the circulation by specific amino acid transporters (Solute Carriers Transporters (SLC)), expressed in the apical and basolateral membranes of the enterocytes [11]. (C) The bioavailability of amino acids and (D) protein consumed can generate multiple nitrogen-derived compounds or contribute to the generation of polyamines, nitric oxide, short-chain fatty acids, and ammonia, among others.
Nutrients 15 03378 g002

2.3. The Role of Gut Microbiota in Amino Acid Catabolism and Generation of End-Products

Studies in germ-free animals reveal that gut bacteria alter the distribution of free amino acids in the gastrointestinal tract, indicating the role of the bacteria in the synthesis or degradation of amino acids. Interestingly, the amount of dietary protein and the dietary protein source modify the gut microbiota [26]. Consequently, this may suggest that the gut microbiota affects the bioavailability of amino acids to the host, depending on the taxonomy of intestinal bacteria. In addition, although short-chain fatty acids (SCFA) are the primary end product of carbohydrate fermentation, many amino acids formed by reductive deamination by bacteria can be precursors of SCFA. Certain bacteria in the small intestine, including Klebsiella spp., Escherichia coli, Streptococcus spp., Succinivibrio dextrinosolvens, Mitsuokella spp., and Anaerovibrio lipolytica, can also utilize protein digestive products and play an essential role in nitrogen recycling [27,28].
Moreover, bacteria species such as Prevotella ruminicola, Butyrivibrio fibrisolvens, Mitsuokella multiacidas, and Streptococcus bovis can secrete active dipeptidyl peptidase and dipeptidase that contribute to protein digestion and absorption of amino acids in the gut [29]. Ammonia is released daily by bacteria through the deamination of amino acids and, to a lesser extent, through urea hydrolysis catalyzed by bacterial urease activity. Up to 3.5–4.0 g of ammonia are released daily in the gut. Ammonia can be used by the bacteria for their metabolism and protein synthesis, absorbed by the colonocytes, transformed into urea in the liver, and excreted in urine [30]. It has been suggested that bacteria in the small intestine may participate in the catabolism of some essential amino acids and modulate the bioavailability of amino acids and their end-products in the systemic circulation of animals and humans. A previous study using conventional and germ-free rats with 15N incorporation into body lysine demonstrated that the N-lysine measured in the host came mainly from bacteria, indicating that amino acids can be exchanged between the host and the microbiota [31].
Although the digestion of dietary protein followed by amino acid absorption is a very efficient process in the small intestine, some nitrogenous material may escape digestion and be transferred into the large intestine. Undigested peptides and amino acids are usually not absorbed by the colonocytes but are fermented by gut microbes into intermediate metabolites and other end-products (Figure 2C), and this will depend on the amount of dietary protein consumed (Figure 2D). Some bacteria genera with proteolytic activity in the large intestine are Bacteroides, Propionibacterium, Streptococcus, Fusobacterium, Clostridium, and Lactobacillus [10,32]. Bacterial degradation of aromatic amino acids in the colonic lumen results in the production of phenolic and indolic compounds, ammonia, polyamines, and hydrogen sulfide [33,34]. Moreover, the catabolism of amino acids in these cells produces multiple metabolites, such as p-cresol from tyrosine, phenylpropionate, phenylacetate from phenylalanine, and indole skatole from tryptophan [30]. Phenolic compounds are primarily absorbed from the colon, detoxified in the colon mucosa and the liver by glucuronide and sulfate conjugation, and excreted in the urine. Decarboxylation of amino acids results in the appearance of amines in the gut. Monoamine and diamine oxidases present in the gut mucosa detoxify the amines produced by the gut microbiota [30].

3. Mechanisms of Regulation of Amino Acid Oxidation

Amino acid catabolism involves several metabolic pathways specific to a particular group of amino acids, involving multiple enzymes, some of which are essential for regulating the flux of metabolites in these pathways and are known as amino acid degrading enzymes (AADEs). AADEs are mainly located in the liver but are now known to be found in other extrahepatic tissues; they are specific for the utilization of each amino acid, and the transcription of the genes encoding them is highly regulated [35]. The study of the molecular mechanisms of regulation of AADEs had a significant breakthrough in the late 1980s and during the 1990s, when the transcriptional regulation of many AADEs by diet and various hormones was elucidated. These investigations provided sufficient information to understand certain key aspects of transcriptional control of AADEs that we now know are highly conserved among the genes of AADEs; however, recent studies have enriched previous knowledge by involving the participation of new players on the scene. Here we describe significant advances in the transcriptional regulation of AADE by diet, gut microbiota metabolites, and various hormones. We also provide recent evidence demonstrating that AADEs are potential targets of miRNAs. Finally, we highlight the importance of amino acid catabolism in epigenetic regulation mechanisms and cell reprogramming.

3.1. Regulation by the Gut Microbiota

Amino acids metabolized by bacteria present in the gut contribute to the survival and proliferation of these bacteria, but also provide amino acids and key metabolites to the host [36]. The generation of these metabolites can also indirectly modulate amino acid degradation in the intestine. For example, it is known that SCFA downregulates the expression of indoleamine 2,3-dioxygenase (IDO-1), a key enzyme involved in tryptophan degradation through the kynurenine pathway, in intestinal epithelial cells [37].
Dietary protein supply can also regulate amino acid catabolism indirectly via changes in the gut microbiota (Figure 2D). The consumption of a high-protein diet impacts the composition of the gut microbiota, favoring the accumulation of protein-fermenting bacteria and reducing the proportion of saccharolytic bacteria [38]. Moreover, the metabolites generated by the gut bacteria due to changes in the amount of dietary protein can indirectly affect the expression of AADE.

3.2. Transcriptional Regulation of Amino Acid Degrading Enzymes

As indicated above, each amino acid has a specific catabolic pathway regulated by key enzymes that play a central role in controlling the flux of the pathway metabolites [39], enzymes known as AADE, some of which are listed in Table 1. Early studies of amino acid catabolism showed that this process occurred mainly in the liver. However, it was later demonstrated that AADEs are present in different organs, particularly the liver, skeletal muscle, kidney, adipose tissue, intestine, and immune cells, among others [40,41,42,43,44]. Interestingly, the BCAA metabolism has some differences since the first step in the catabolism of BCAA is catalyzed by BCAT, an enzyme that is located in extrahepatic tissues, including skeletal muscle [45], the heart, kidney, brain, intestine, and adipose tissue, and in fetal rat liver [46]. The expression of these catabolic enzymes is highly responsive to the amount of dietary protein. Most of the AADEs are upregulated in the liver by the consumption of high-protein diets, indicating that the excess of protein will most likely be catabolized [44] because there is no amino acid reservoir in the body [42,47].
Interestingly, the increased activity of these enzymes is due to an up regulation of AADE gene expression, as several studies have reported in mice or rats fed increasing amounts of dietary proteins showing an increment in the abundance of AADE mRNA in the liver, and the higher the amount of dietary proteins, the higher the expression of most of the enzymes [12,44,51]. Interestingly, when protein intake is above the protein requirement, there is also a significant increase in the abundance of BCAT in skeletal muscle [12]. After consuming high protein diets, glucagon levels increase, which stimulates the gene expression of AADE in the liver to catabolize the excess amino acids [51,52]. Similarly, during fasting, there is an increase in glucagon, which, through cAMP, also increases the expression of the AADE gene, leading to increased ATP synthesis and gluconeogenesis [53] (Figure 3A). In addition to glucagon, the fasting state increases the circulating levels of glucocorticoids [54]. Thus, transcriptional regulation studies have been conducted to establish the mechanism of action of glucocorticoids (dexamethasone) and glucagon on AADE gene expression. The first studies using the gene of tryptophan dioxygenase 2 (TDO2) showed that deletion of the 5′ region of its promoter causes the loss of regulation by dexamethasone [55]. Two response elements have been identified for glucocorticoids (GRE) at −450 bp and −1.2 kb upstream of the transcription start site of the TDO2 gene, which have common sequences GGTACANNNTGTT [56]. Further studies on other AADEs such as serine dehydratase (SDS) revealed that the −133 to −33 bp region is essential for its gene expression since a complete loss of activity is observed when this region is deleted, attributing the regulation to the transcription factors HNF1 and HNF4α [57]. It was later demonstrated that glucocorticoids and glucagon activate HNF4α [58]. In fact, recent studies indicate that the gene expression of the SDS gene is upregulated by the transcription factor HNF4α [59]. On the other hand, it was shown that two CREB response elements (CRE), designated CRE1 and CRE2, at approximately −3.5 kb from the transcription start site of the gene, also induced the expression of the SDS gene. Mutations of both CRE sites that are spliced partially decrease the activation of SDS gene transcription by cAMP, indicating that glucagon can directly stimulate the transcription rate of the SDS gene via protein kinase A (PKA). CRE sites are considered classic enhancers that positively stimulate the expression of SDS and other AADEs. Interestingly, dexamethasone can increase the binding of CREB to CRE sites by stimulating their phosphorylation [60]. Studies with another AADE, such as histidase (HAL), have revealed the presence of several response elements for various transcription factors, such as C/EBP, NF-IL6, HNF4α, progesterone and glucocorticoid receptors, and CREB in the regulatory region of its gene. The presence of CRE elements in the region between −340 and −815 bp reinforced the evidence that glucagon stimulates HAL gene expression via CREB [61]. In addition, stimulation with phorbol 12-myristate, 13-acetate (PMA) also activates the HAL promoter, indicating that gene expression of this catabolizing enzyme gene can also be stimulated via PKC [61]. Recently, HNF4α has been found to regulate the GLS2 promoter positively, and the response elements for HNF4 are conserved between human, mouse, and rabbit [62], response element also found in the SDS and HAL promoters [59,63]. Analysis of other AADE such as glutaminase 2 or tyrosine aminotransferase gene promoters, also provides evidence of the presence of response elements for CRE, HNF1, HNF-5, and GRE [64,65]. Interestingly, PPARα is known to promote proteasomal degradation of HNF4α, decreasing the transcription of AADE, but at the same time promoting the expression of fatty acid oxidation enzymes, resulting in a switch-off mechanism to prevent amino acid oxidation but activating the utilization of fatty acids as an energy source [63].
In addition, other conditions can induce the expression of specific AADEs. BCAA catabolism also increases in the fetal liver during gestation [46,66] and the mammary gland during lactation. In the last case, the high rate of blood flow to the mammary gland during lactation produces retention of BCAA in the gland, which exceeds the requirements for milk synthesis, stimulating the catabolism of BCAA, especially leucine [67]. The amino acid catabolism in the liver results in an increase in NH4+ production and an increase in the amino acid carbon skeletons. As a consequence, the enzymes of the urea cycle increase their expression with a high-protein diet [68] to eliminate the excess of NH4+. Other studies have shown that not only an excess of dietary protein induces the expression of these enzymes, but that prolonged fasting or the ingestion of very low concentrations of dietary protein increases muscle protein breakdown, releasing amino acids into the circulation, particularly glutamine and alanine, that are catabolized in the liver [54].

3.3. Regulation of Amino Acid Catabolizing Enzymes by miRNAs

In addition to transcriptional control, post-transcriptional control mechanisms can regulate the expression of AADE, particularly by some microRNAs (miRNAs). miRNAs are short 18–22 nucleotide, single-stranded RNA molecules that regulate gene expression by binding to 3′-UTR regions of mRNA target genes, leading to their degradation and/or translational repression [69]. Therefore, they can regulate and control metabolism by modifying gene expression. The first evidence suggesting miRNAs can regulate amino acid metabolism pathways was found after screening conserved 3′-UTR regions for potential miRNA targets in Drosophila melanogaster. It was found that miR-277 may be involved in regulating several enzymes of BCAA catabolism [70]. These results were validated when it was shown that miR-277 regulates BCAA catabolism by repressing the branched-chain α-ketoacid dehydrogenase (BCKDH) enzyme complex, thereby modifying the BCAA/BCKA ratio and activating TOR kinase, in turn affecting insulin signaling. It was also demonstrated that if miR277 is either expressed constitutively or inhibited, lifespan is shortened, especially when flies are fed high-protein/low carbohydrate diets, and dietary restriction attenuates these observations [71]. There is limited information in mammals, but it has been shown that miR29b prevents translation of the dihydrolipoamide branched-chain acyltransferase component of the BCKDH complex in HEK293 cell culture [72]. Elevated levels of circulating BCAA have been associated with the risk of obesity and type 2 diabetes, so it could be of great value to study whether miR29b expression is modified in these conditions.
Nutrients 15 03378 g003 550
Figure 3. Transcriptional and post-transcriptional regulation of amino acid degrading enzymes and generation of amino acid derived metabolites as modulators of epigenetics. (A) The consumption of a high-protein diet induces the release of glucagon, which activates an intracellular Gαs-coupled proteinspathway after binding to its seven transmembrane receptors on the plasma membrane. This consequently increases cAMP levels via the activation of adenylate cyclase, which stimulates the activation of protein kinase A (PKA) and the cAMP response element-binding (CREB) protein. Phosphorylated CREB induces the transcription of several amino acid degrading enzymes in the liver, through its binding to specific response elements in their promoter regions. (B) Amino acid degrading enzymes can also be targets of some microRNAs (miRNAs), leading to their degradation and/or translational repression. Both miR277 and miR29b prevent the translation of proteins of the BCKDH enzyme complex [71,72], modifying the branched-chain amino acids/branched-chain alpha-keto acids ratio and activating TOR kinase, which regulates insulin signaling. miR122 inhibits the translation of mitochondrial glutaminase and its transporter, the Solute Carrier (SLC)1a5, thereby inhibiting glutaminolysis and enhancing gluconeogenesis in the liver [73]. (C) Amino acid degrading pathways provide metabolites that influence epigenetic modifications of chromatin that modulate gene expression. Methionine, threonine, serine, glycine, and histidine act as methyl donors; the generation of S-Adenosyl methionine (SAM) via the one-carbon metabolism plays a key role in epigenetic modification through DNA and histone methylation regulated by the activation of DNA methyltransferases (DNMT) and histone methyltransferases (HMT), respectively. (D) Catabolism of arginine, proline, histidine, glutamate, and glutamine can result in the generation of the epigenetic metabolite alpha-ketoglutarate (α-KG), which is used as a substrate for Jumonji C-domain lysine demethylases (KDM2-7) and ten-once translocation hydroxylases (TET1-3), enzymes responsible for histone and DNA demethylation, respectively. P5C: pyrroline-5-carboxylate.
Figure 3. Transcriptional and post-transcriptional regulation of amino acid degrading enzymes and generation of amino acid derived metabolites as modulators of epigenetics. (A) The consumption of a high-protein diet induces the release of glucagon, which activates an intracellular Gαs-coupled proteinspathway after binding to its seven transmembrane receptors on the plasma membrane. This consequently increases cAMP levels via the activation of adenylate cyclase, which stimulates the activation of protein kinase A (PKA) and the cAMP response element-binding (CREB) protein. Phosphorylated CREB induces the transcription of several amino acid degrading enzymes in the liver, through its binding to specific response elements in their promoter regions. (B) Amino acid degrading enzymes can also be targets of some microRNAs (miRNAs), leading to their degradation and/or translational repression. Both miR277 and miR29b prevent the translation of proteins of the BCKDH enzyme complex [71,72], modifying the branched-chain amino acids/branched-chain alpha-keto acids ratio and activating TOR kinase, which regulates insulin signaling. miR122 inhibits the translation of mitochondrial glutaminase and its transporter, the Solute Carrier (SLC)1a5, thereby inhibiting glutaminolysis and enhancing gluconeogenesis in the liver [73]. (C) Amino acid degrading pathways provide metabolites that influence epigenetic modifications of chromatin that modulate gene expression. Methionine, threonine, serine, glycine, and histidine act as methyl donors; the generation of S-Adenosyl methionine (SAM) via the one-carbon metabolism plays a key role in epigenetic modification through DNA and histone methylation regulated by the activation of DNA methyltransferases (DNMT) and histone methyltransferases (HMT), respectively. (D) Catabolism of arginine, proline, histidine, glutamate, and glutamine can result in the generation of the epigenetic metabolite alpha-ketoglutarate (α-KG), which is used as a substrate for Jumonji C-domain lysine demethylases (KDM2-7) and ten-once translocation hydroxylases (TET1-3), enzymes responsible for histone and DNA demethylation, respectively. P5C: pyrroline-5-carboxylate.
Nutrients 15 03378 g003
Another example of the importance of miRNAs in the regulation of AADE is that of miR-122, which regulates glutamine metabolism in the liver by inhibiting mitochondrial glutaminase (Gls) and its transporter, Slc1a5, thereby inhibiting glutaminolysis and enhancing gluconeogenesis in humans and mice [73]. Since many tumors are highly dependent on glutamine as an energy source [74], targeting miR-122 for cancer treatment might be possible. This recent evidence shows the involvement of miRNAs in the regulation of the translation of proteins involved in amino acid catabolism [75], which is summarized in Figure 3B.

3.4. Amino Acid Catabolism and Epigenetics, Tissue Plasticity and Cellular Reprogramming

Nutrients can regulate the metabolic activities of living organisms through epigenetic mechanisms, including DNA methylation, histone modification, and RNA regulation [76]. Amino acid degradation pathways provide epigenetic metabolites that influence these processes. For example, some amino acids, particularly, methionine, glycine, histidine, and serine, act as dietary methyl donors and play a key role in epigenetic modification through DNA and protein methylation and one-carbon metabolism in the body [77] (Figure 3C). In addition, catabolism of arginine, proline, histidine, glutamate, and glutamine can result in the formation of alpha-ketoglutarate (α-KG), an epigenetic metabolite that is used as a substrate for enzymes responsible for epigenetic modifications of chromatin that modulate gene expression [78]. Among these enzymes, α-KG is utilized by Jumonji C-domain lysine demethylases (KDM2-7) [79], which are considered the major histone demethylases; and by ten-once translocation hydroxylases (TET1-3), which are involved in DNA demethylation and catalyze the oxidative decarboxylation of α-KG to produce 5-hydroxymethylcytosine (5-hmC) [80,81] (Figure 3D). In addition, some enzymes involved in amino acid degradation can be considered epigenetic regulators; this is the case of proline dehydrogenase, located in the mitochondrial inner membrane, which converts proline to pyrroline-5-carboxylate (P5C) and provides electrons to the electron transport chain [82]. This enzyme is under the regulation of p53 and PPARα, and its activation promotes the generation of ROS, which in turn generates epigenetic changes to induce the expression of the genetic program of antioxidant enzymes, cell cycle arrest, and autophagy [83,84].
Moreover, amino acid degradation produces downstream metabolites that are critical for embryonic stem cell (ESC) function and differentiation. Evidence from several laboratories reports that differentiation and self-renewal of mouse ESCs are dependent on proline catabolism. Likewise, catabolism of either threonine (mouse) or methionine (human) generates molecules used in histone methylation and acetylation involved in ESC differentiation and growth [85].

4. Amino Acid Catabolism in Health and Disease

Amino acid catabolism provides metabolites that serve as substrates or are responsible for activating signaling pathways involved in the physiology of different organs. For example, the regulation of amino acid catabolism is key for the immune system since its functions depend on an adequate supply of amino acids, and individual amino acids and their metabolites can affect immune responses [5]. Similarly, amino acid catabolism dysregulation can contribute to the development, or progression of pathological processes involved in the presence of insulin resistance [86]. Here we provide evidence for the importance of amino acid turnover and catabolism in health and disease, opening the landscape to new mechanisms regulated by amino acids and their metabolites beyond their known functions for protein synthesis and energy fuel.

4.1. Amino Acid Catabolism and Immunity

All cells, including those involved in immune responses, depend on nutrient availability to maintain their functionality [87]. When there is an inflammatory or antigenic cue, immune cells need more amino acids to remain viable and respond accordingly, so they must adapt rapidly to any shortage of amino acids [88]. This adaptation suggests that any modification in amino acid (and other nutrient) metabolism will also affect the immune response in different ways, depending on the specific nutrient and energy requirements of the cells and, thus, their function [89,90]. In other words, each immune cell’s microenvironment will be directly related to their response to nutrient availability. Both the innate and adaptive immune systems require an adequate supply of amino acids to synthesize molecules such as histamine, glutathione, and nitric oxide, among others, but especially for immunoglobulins and cytokine activation, as well as for antibody production through mTOR signaling by BCAA [91]. Therefore, individual amino acids and their metabolites can affect immune responses.
Besides BCAA, the AADE that have been mainly studied for their response to inflammation are those involved in tryptophan and arginine catabolism, such as tryptophan 2,3-dioxygenase (TDO), IDO1, the arginase isoforms (ARG1, ARG2), and the inducible nitric oxide synthase (iNOS), respectively [92].

4.1.1. Tryptophan Catabolism

TDO and IDO catalyze the cleavage of the C2–C3 bond of the indolic ring of L-tryptophan to form N-formyl-kynurenine [93]. Noteworthy, this pathway is essential for NAD+ synthesis, which is necessary to control ATP production and macrophage activation and function. Although both enzymes catalyze the same reaction, they differ in expression and function [94]. TDO is mainly expressed in the liver and is induced by tryptophan, glucocorticoids, and kynurenine. Because it catabolizes excess dietary tryptophan, it may indirectly control serotonin production [95], which, among other things, can modulate cytokine release and leucocyte recruitment during inflammation responses [96]. Also, it has been shown that active TDO is highly expressed in tumor cells, and its expression contributes to tumoral immune resistance [97].
IDO1, the rate-limiting step of tryptophan degradation, is extrahepatic and is induced by lipopolysaccharide (LPS), TNF-α (tumor necrosis factor-α), and IFN-γ (interferon-γ) [98,99] (Figure 4A). The latter induces host cells to degrade tryptophan in response to a bacterial infection, therefore blocking the growth of bacteria by limiting this amino acid [100]. Moreover, upon interferon induction, some antigen-presenting cells, including macrophages and dendritic cells, also express IDO1 to deplete amino acids in the intestinal lumen and regulate the immune response in the intestinal barrier [92]. It has also been shown that IDO expression in dendritic cells can increase regulatory T cells (Tregs) through activation of the aryl hydrocarbon receptor (AHR) [101]; however, whether the increase in Tregs is due to a reduction in tryptophan concentration or by kynurenine production is still a matter of debate.

4.1.2. Arginine Catabolism

L-arginine is a common substrate for arginase-1 (Arg1) and inducible nitric oxide synthase (iNOS); thus, its regulation is essential for proper cellular functioning [102]. Arg1 produces urea and L-ornithine from L-arginine, while iNOS converts the latter into L-citrulline, producing nitric oxide (NO) [103]. Macrophages are part of the innate immune system and respond to invading bacteria, viruses, fungi, and even cancer cells, changing their phenotype [104]. The two main phenotypes are classically activated macrophages (M1) and alternatively activated macrophages (M2) [105]. M1 macrophages are activated by LPS and IFN-γ producing pro-inflammatory cytokines, while M2 macrophages are activated by IL4, IL13, and lactic acid and produce anti-inflammatory cytokines [106,107]. Interestingly, among other differences between both phenotypes, M1 macrophages express iNOS to produce NO as a microbicidal agent, and M2 macrophages express Arg-1 to increase polyamine synthesis from ornithine and promote wound healing and tissue fibrosis [108,109]. These examples show that amino acid catabolism is key for the energy and functional demands of the intestinal epithelium, such as the regulation of the intestinal barrier and immune response [110]. A more detailed description of the involvement of amino acids and their catabolism in immune responses is reviewed elsewhere [5,88,92,110,111].

4.2. Amino Acid Catabolism in Obesity and Diabetes

An adequate amino acid catabolism is crucial to maintaining plasma amino acid concentration. Disturbances in plasma amino acid concentration have been associated with alterations in individual health [86]. In a cross-sectional study with young adults, it has been observed that subjects with obesity have higher levels of alanine, aspartate, cysteine, ornithine, phenylalanine, proline, and tyrosine and lower levels of glycine, ornithine, and serine compared to normal weight subjects [112]. Furthermore, subjects with insulin resistance (IR) (defined as HOMA > 2.5) have higher levels of arginine, alanine, aspartate, isoleucine, leucine, phenylalanine, proline, tyrosine, taurine, and valine than subjects without IR [112]. In addition, increased levels of BCAA and aromatic amino acids are associated with a five-fold increased risk of developing type 2 diabetes [113,114]. BCAAs play important general roles in the body, including regulation of protein synthesis through mTOR and as a source of energy during exercise, which have been extensively reviewed elsewhere [115]. However, there is significant controversy as to whether altered plasma concentrations of amino acids, especially BCAA, are a cause or consequence of obesity or insulin resistance. Unlike the rest of the amino acids, as mentioned above, the first enzymatic reaction of BCAA catabolism is extrahepatic, with muscle, kidney, and adipose tissue as the principal organs for BCAA transamination (Figure 4B). Notably, BCAA catabolism is mainly impaired in adipose tissue during obesity. Branched-chain aminotransferase 2 (BCAT2), an isoform of BCAT found in mitochondria, and BCKDH activity are reduced in the adipose tissue of mice and rats with genetic or diet-induced obesity [116,117,118,119]. In subjects with obesity, BCAT2 and BCKDH expression is reduced mainly in visceral adipose tissue [43,117]. Nevertheless, further research is needed to clarify the mechanisms responsible for the decreased expression and activity of BCAT2 and BCKDH in adipose tissue during obesity.
The alteration of BCAA catabolism has physiological consequences in two aspects. First, leucine is likely the most potent mTORC1 activator among all amino acids. In physiological conditions, mTORC1 activation inhibits autophagy, activates adipogenesis and lipogenesis in white adipose tissue, and inhibits insulin signaling through the inactivation of the insulin receptor substrate 1 (IRS1) (Figure 4C). Thus, high leucine concentrations could induce an overactivation of mTORC1, leading to insulin resistance and, thus, an increase in glucose levels [120,121]. The use of rapamycin, a known mTORC1 inhibitor, prevents glucose intolerance induced by a diet high in fat and BCAA [122].
Furthermore, leucine catabolism contributes 30% to the acetyl-CoA lipogenic pool [123]. and acetyl-CoA can be converted into malonyl-CoA by acetyl-CoA carboxylase (ACC). Malonyl-CoA is the preferred substrate of fatty acid synthase (FAS). Thus, leucine is extensively incorporated into the lipid fraction of functional adipocytes. Incorporation that is significantly reduced in adipocytes from high-fat fed rats [118]. In addition to fatty acids, the carbon skeleton of leucine could be a substrate for synthesizing phospholipids and cholesterol. An increase in cholesterol-synthetizing enzymes has been demonstrated, which use 3-hydroxy-3-methylglutaryl-CoA, an intermediate of leucine catabolism, as a substrate during adipogenesis [124]. Taken together, this evidence suggests that decreased catabolism of BCAA could reduce the production and storage of FA and cholesterol in adipose tissue, affecting its functionality.
Second, a reduction in the BCAA catabolic enzymes causes an inefficient production of anaplerotic substrates from BCAA, causing suboptimal activity of the Krebs cycle [125,126]. These results have important implications for the understanding of metabolic inflexibility. Until now, metabolic flexibility has only been assessed in terms of how glucose affects lipid metabolism and vice versa. However, new evidence suggests that amino acid catabolism needs to be evaluated in terms of metabolic flexibility because amino acid availability and catabolic amino acid metabolites can also affect lipid and carbohydrate metabolism, as in the model proposed by Muoio, where chronic overfeeding causes a mitochondrial blockade affecting glucose, fatty acid, and BCAA oxidation [127].
Although progress has been made in understanding the participation of BCAA catabolism in the maintenance of adipocyte function, further research is needed to understand the role of catabolism of other amino acids such as aspartate, proline, tyrosine, and tryptophan, among others, that can modify mitochondrial activity and therefore metabolic flexibility in the adipocyte.
In addition to BCAAs, tryptophan (Trp) is another essential amino acid for humans, [128]. Consumed tryptophan is mainly used for protein synthesis; however, this amino acid can be used in about 5% of cases as a precursor for the synthesis of serotonin, N-acetyl serotonin, and melatonin [129]. Interestingly, a part of free tryptophan is also catabolized through the tryptophan-kynurenine pathway [130]. Recent studies have found that certain metabolites of tryptophan catabolism participate in the development of T2D [131]. A significant association between low plasma Trp concentrations has been reported in obese subjects with metabolic syndrome, in whom insulin resistance is common [132]. Evidence suggests that metabolites of the kynurenine pathway increase with insulin resistance before the clinical manifestation of hyperglycemia [133]. Gene expression of tryptophan catabolism limiting enzymes to kynurenine, such as indolamine 2,3-dioxygenase 1 (IDO1), indolamine 2,3-dioxygenase 2 (IDO2), and tryptophan 2,3-dioxygenase (TDO2), is shown to increase in patients with T2D [134]. A possible mechanism by which metabolites of the Trp-Kynurenine pathway contribute to the development of insulin resistance includes the possible formation of chelate complexes between xanthurenic acid and insulin, which are indistinguishable from free insulin but have ∼50% less activity than insulin [135]. However, studies are still needed to determine the importance of the regulation of gene expression by the step-limiting enzyme of the Trp- Kynurenine pathway in the pathogenesis of diabetes or its complications. On the other hand, Trp and phenylalanine interact with the GPR142 receptor, increasing insulin secretion and the incretins GIP and GLP-1, improving circulating glucose levels [136], suggesting that the decrease in Trp during obesity will decrease insulin secretion and contribute to the progression to T2D of subjects with obesity.

4.3. Amino Acid Catabolism and Thermogenesis

In addition to white adipose tissue, it has been demonstrated that BAT may play an essential role in the control of body thermogenesis [137]. This effect is in part mediated by the presence of the uncoupling protein 1 (UCP1), which can use the proton gradient generated in the mitochondria by the respiratory chain in order to produce heat [138]. The energy sources used by BAT mitochondria are fatty acids and glucose [139]. Interestingly, recent evidence has demonstrated that BAT mitochondria can use BCAA amino acids as an energy source to increase thermogenesis (Figure 4D). BAT is now known to express enzymes of the amino acid catabolic pathways for BCAA, including BCAT2 and BCKDH. Under conditions of cold exposure, where thermogenesis is upregulated, there is a significantly increased uptake of BCAA by BAT, particularly valine and leucine. The importance of BCAA oxidation for thermogenesis has been demonstrated since the absence of BCKDH expression in BAT impairs energy homeostasis, especially during cold exposure. BCAA oxidation occurs in the mitochondria, and it is known that BCAAs are transported into the mitochondria by the SLC25A44 transporter. Surprisingly, the deletion of SLC25A44 impairs BAT thermogenesis [140].
As previously mentioned, white adipose tissue plays an important role in the utilization of BCAAs, which is associated with improving insulin sensitivity. However, now BAT is also considered an essential catabolic organ of these amino acids, decreasing circulating levels of BCAA that are associated with increased insulin sensitivity.

5. Conclusions

Amino acid catabolism has been considered in nutrition as a mechanism used by the body to eliminate excess circulating amino acids due to high-protein intake or a catabolic state of the organism, as occurs during fasting or in specific pathologies. However, research in nutrition and metabolism has shown that amino acid catabolism plays an essential role in different metabolic processes, even though it has long been overlooked. It is now important to consider it as a key element of metabolism whose abnormalities may be associated with the development of several chronic diseases. Amino acid catabolism enzymes have been found in different cell types or organs and perform specific functions, generating end-products that can be used for ATP synthesis and gluconeogenesis. However, its role is now known to have additional functions of great relevance, such as the regulation of the immune response, the development of insulin resistance, and even body thermogenesis. It is important to comprehensively consider not only the utilization of dietary amino acids as precursors for the synthesis of proteins and other nitrogenous compounds, but also that their utilization by the catabolism machinery generates important metabolites that have an impact on the regulation of gene expression that directly or indirectly impacts the fine regulation of numerous processes in various cell types of various organs or tissues. Interestingly, new important players in the orchestration of amino acid catabolism have been discovered, particularly the gut microbiota. Thus, the field of nutrition must take into more profound and more applicative consideration the effects of amino acid catabolism. In particular, the catabolism of BCAAs needs to be studied in greater depth, as current evidence strongly suggests its implications in various metabolic processes, and it is therefore important to conduct more clinical trials to use this information in the development of dietary guidelines or therapeutic strategies involved in the future of personalized nutrition.

Author Contributions

N.T.: Investigation, Writing, Review, and Editing. S.T.-C.: Investigation, Writing. L.A.V.-V.: Investigation, Writing, Methodology. L.G.N.: Investigation, Writing. G.A.-E.: Investigation, Writing. A.R.T.: Conceptualization, Writing. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by CONACYT (grant No. 256552-M to A.R.T).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

Figures were created with Biorender.com.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Chou, C.J.; Affolter, M.; Kussmann, M. A nutrigenomics view of protein intake: Macronutrient, bioactive peptides, and protein turnover. Prog. Mol. Biol. Transl. Sci. 2012, 108, 51–74. [Google Scholar] [CrossRef]
  2. Harper, A.E.; Miller, R.H.; Block, K.P. Branched-chain amino acid metabolism. Annu. Rev. Nutr. 1984, 4, 409–454. [Google Scholar] [CrossRef] [PubMed]
  3. Bender, D.A. The metabolism of “surplus” amino acids. Br. J. Nutr. 2012, 108 (Suppl. S2), S113–S121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Bartlett, A.; Kleiner, M. Dietary protein and the intestinal microbiota: An understudied relationship. iScience 2022, 25, 105313. [Google Scholar] [CrossRef] [PubMed]
  5. Tome, D. Amino acid metabolism and signalling pathways: Potential targets in the control of infection and immunity. Nutr. Diabetes 2021, 11, 20. [Google Scholar] [CrossRef] [PubMed]
  6. Broer, S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol. Rev. 2008, 88, 249–286. [Google Scholar] [CrossRef] [Green Version]
  7. Loveday, S.M. Protein digestion and absorption: The influence of food processing. Nutr. Res. Rev. 2022, 16, 1–16. [Google Scholar] [CrossRef]
  8. Bertrand, J.; Goichon, A.; Dechelotte, P.; Coeffier, M. Regulation of intestinal protein metabolism by amino acids. Amino Acids 2013, 45, 443–450. [Google Scholar] [CrossRef]
  9. Sleisenger, M.H.; Kim, Y.S. Protein digestion and absorption. N. Engl. J. Med. 1979, 300, 659–663. [Google Scholar] [CrossRef]
  10. Davila, A.M.; Blachier, F.; Gotteland, M.; Andriamihaja, M.; Benetti, P.H.; Sanz, Y.; Tome, D. Intestinal luminal nitrogen metabolism: Role of the gut microbiota and consequences for the host. Pharmacol. Res. 2013, 68, 95–107. [Google Scholar] [CrossRef]
  11. Chen, C.; Yin, Y.; Tu, Q.; Yang, H. Glucose and amino acid in enterocyte: Absorption, metabolism and maturation. Front. Biosci. 2018, 23, 1721–1739. [Google Scholar] [CrossRef] [Green Version]
  12. Torres, N.; Lopez, G.; De Santiago, S.; Hutson, S.M.; Tovar, A.R. Dietary protein level regulates expression of the mitochondrial branched-chain aminotransferase in rats. J. Nutr. 1998, 128, 1368–1375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Ma, N.; Ma, X. Dietary Amino Acids and the Gut-Microbiome-Immune Axis: Physiological Metabolism and Therapeutic Prospects. Compr. Rev. Food Sci. Food Saf. 2019, 18, 221–242. [Google Scholar] [CrossRef]
  14. Pink, D.B.; Gatrell, S.K.; Elango, R.; Turchinsky, J.; Kiess, A.S.; Blemings, K.P.; Dixon, W.T.; Ball, R.O. Lysine alpha-ketoglutarate reductase, but not saccharopine dehydrogenase, is subject to substrate inhibition in pig liver. Nutr. Res. 2011, 31, 544–554. [Google Scholar] [CrossRef]
  15. Mitchell, A.D.; Benevenga, N.J. The role of transamination in methionine oxidation in the rat. J. Nutr. 1978, 108, 67–78. [Google Scholar] [CrossRef]
  16. Cooper, A.J.; Meister, A. Comparative studies of glutamine transaminases from rat tissues. Comp. Biochem. Physiol. B Biochem. 1981, 69, 137–145. [Google Scholar] [CrossRef]
  17. Schaart, M.W.; Schierbeek, H.; van der Schoor, S.R.; Stoll, B.; Burrin, D.G.; Reeds, P.J.; van Goudoever, J.B. Threonine utilization is high in the intestine of piglets. J. Nutr. 2005, 135, 765–770. [Google Scholar] [CrossRef] [Green Version]
  18. Hoerr, R.A.; Matthews, D.E.; Bier, D.M.; Young, V.R. Effects of protein restriction and acute refeeding on leucine and lysine kinetics in young men. Am. J. Physiol. 1993, 264, E567–E575. [Google Scholar] [CrossRef]
  19. Wu, G. Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs. Am. J. Physiol. 1997, 272, G1382–G1390. [Google Scholar] [CrossRef]
  20. Bush, J.A.; Wu, G.; Suryawan, A.; Nguyen, H.V.; Davis, T.A. Somatotropin-induced amino acid conservation in pigs involves differential regulation of liver and gut urea cycle enzyme activity. J. Nutr. 2002, 132, 59–67. [Google Scholar] [CrossRef] [Green Version]
  21. Morris, S.M., Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 2002, 22, 87–105. [Google Scholar] [CrossRef]
  22. Wu, G.; Morris, S.M., Jr. Arginine metabolism: Nitric oxide and beyond. Biochem. J. 1998, 336 Pt 1, 1–17. [Google Scholar] [CrossRef] [PubMed]
  23. Kan, C.C.; Chung, T.Y.; Juo, Y.A.; Hsieh, M.H. Glutamine rapidly induces the expression of key transcription factor genes involved in nitrogen and stress responses in rice roots. BMC Genom. 2015, 16, 731. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Mouille, B.; Robert, V.; Blachier, F. Adaptative increase of ornithine production and decrease of ammonia metabolism in rat colonocytes after hyperproteic diet ingestion. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287, G344–G351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Piper, D.W.; Fenton, B.H. pH stability and activity curves of pepsin with special reference to their clinical importance. Gut 1965, 6, 506–508. [Google Scholar] [CrossRef] [Green Version]
  26. Sanchez-Tapia, M.; Moreno-Vicencio, D.; Ordaz-Nava, G.; Guevara-Cruz, M.; Granados-Portillo, O.; Vargas-Castillo, A.; Torres, N.; Tovar, A.R. Antibiotic Treatment Reduces the Health Benefits of Soy Protein. Mol. Nutr. Food Res. 2020, 64, e2000532. [Google Scholar] [CrossRef]
  27. Dai, Z.L.; Li, X.L.; Xi, P.B.; Zhang, J.; Wu, G.; Zhu, W.Y. Metabolism of select amino acids in bacteria from the pig small intestine. Amino Acids 2012, 42, 1597–1608. [Google Scholar] [CrossRef]
  28. Dai, Z.L.; Zhang, J.; Wu, G.; Zhu, W.Y. Utilization of amino acids by bacteria from the pig small intestine. Amino Acids 2010, 39, 1201–1215. [Google Scholar] [CrossRef]
  29. Fan, P.; Liu, P.; Song, P.; Chen, X.; Ma, X. Moderate dietary protein restriction alters the composition of gut microbiota and improves ileal barrier function in adult pig model. Sci. Rep. 2017, 7, 43412. [Google Scholar] [CrossRef] [Green Version]
  30. Windey, K.; De Preter, V.; Verbeke, K. Relevance of protein fermentation to gut health. Mol. Nutr. Food Res. 2012, 56, 184–196. [Google Scholar] [CrossRef]
  31. Torrallardona, D.; Harris, C.I.; Coates, M.E.; Fuller, M.F. Microbial amino acid synthesis and utilization in rats: Incorporation of 15N from 15NH4Cl into lysine in the tissues of germ-free and conventional rats. Br. J. Nutr. 1996, 76, 689–700. [Google Scholar] [CrossRef] [Green Version]
  32. Macfarlane, G.T.; Allison, C.; Gibson, S.A.; Cummings, J.H. Contribution of the microflora to proteolysis in the human large intestine. J. Appl. Bacteriol. 1988, 64, 37–46. [Google Scholar] [CrossRef] [PubMed]
  33. Blachier, F.; Mariotti, F.; Huneau, J.F.; Tome, D. Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences. Amino Acids 2007, 33, 547–562. [Google Scholar] [CrossRef] [PubMed]
  34. Macfarlane, G.T.; Gibson, S.A.; Beatty, E.; Cummings, J.H. Estimation of short-chain fatty acid production from protein by human intestinal bacteria based on branched-chain fatty acid measurements. FEMS Microbiol. Lett. 1992, 101, 81–88. [Google Scholar]
  35. Desvergne, B.; Michalik, L.; Wahli, W. Transcriptional regulation of metabolism. Physiol. Rev. 2006, 86, 465–514. [Google Scholar] [CrossRef]
  36. Libao-Mercado, A.J.; Zhu, C.L.; Cant, J.P.; Lapierre, H.; Thibault, J.N.; Seve, B.; Fuller, M.F.; de Lange, C.F. Dietary and endogenous amino acids are the main contributors to microbial protein in the upper gut of normally nourished pigs. J. Nutr. 2009, 139, 1088–1094. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Martin-Gallausiaux, C.; Larraufie, P.; Jarry, A.; Beguet-Crespel, F.; Marinelli, L.; Ledue, F.; Reimann, F.; Blottiere, H.M.; Lapaque, N. Butyrate Produced by Commensal Bacteria Down-Regulates Indolamine 2,3-Dioxygenase 1 (IDO-1) Expression via a Dual Mechanism in Human Intestinal Epithelial Cells. Front. Immunol. 2018, 9, 2838. [Google Scholar] [CrossRef] [Green Version]
  38. Zhao, J.; Zhang, X.; Liu, H.; Brown, M.A.; Qiao, S. Dietary Protein and Gut Microbiota Composition and Function. Curr. Protein Pept. Sci. 2019, 20, 145–154. [Google Scholar] [CrossRef]
  39. Zhao, M.; Qu, H. Human liver rate-limiting enzymes influence metabolic flux via branch points and inhibitors. BMC Genom. 2009, 10 (Suppl. S3), S31. [Google Scholar] [CrossRef] [Green Version]
  40. Hoffmann, D.; Dvorakova, T.; Schramme, F.; Stroobant, V.; Van den Eynde, B.J. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance. Front. Immunol. 2020, 11, 601759. [Google Scholar] [CrossRef]
  41. Labow, B.I.; Souba, W.W.; Abcouwer, S.F. Mechanisms governing the expression of the enzymes of glutamine metabolism—Glutaminase and glutamine synthetase. J. Nutr. 2001, 131, 2467S–2474S; discussion 2486S-2487S. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Ogawa, H.; Fujioka, M.; Su, Y.; Kanamoto, R.; Pitot, H.C. Nutritional regulation and tissue-specific expression of the serine dehydratase gene in rat. J. Biol. Chem. 1991, 266, 20412–20417. [Google Scholar] [CrossRef] [PubMed]
  43. Serralde-Zuniga, A.E.; Guevara-Cruz, M.; Tovar, A.R.; Herrera-Hernandez, M.F.; Noriega, L.G.; Granados, O.; Torres, N. Omental adipose tissue gene expression, gene variants, branched-chain amino acids, and their relationship with metabolic syndrome and insulin resistance in humans. Genes Nutr. 2014, 9, 431. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Torres, N.; Martinez, L.; Aleman, G.; Bourges, H.; Tovar, A.R. Histidase expression is regulated by dietary protein at the pretranslational level in rat liver. J. Nutr. 1998, 128, 818–824. [Google Scholar] [CrossRef] [Green Version]
  45. Torres, N.; Tovar, A.R.; Harper, A.E. Metabolism of Valine in rat skeletal muscle mitochondria. J. Nutr. Biochem. 1993, 4, 681–689. [Google Scholar] [CrossRef]
  46. Torres, N.; Vargas, C.; Hernandez-Pando, R.; Orozco, H.; Hutson, S.M.; Tovar, A.R. Ontogeny and subcellular localization of rat liver mitochondrial branched chain amino-acid aminotransferase. Eur. J. Biochem. 2001, 268, 6132–6139. [Google Scholar] [CrossRef]
  47. Watford, M.; Vincent, N.; Zhan, Z.; Fannelli, J.; Kowalski, T.; Kovacevic, Z. Transcriptional control of rat hepatic glutaminase expression by dietary protein level and starvation. J. Nutr. 1994, 124, 493–499. [Google Scholar] [CrossRef] [PubMed]
  48. Fagerberg, L.; Hallstrom, B.M.; Oksvold, P.; Kampf, C.; Djureinovic, D.; Odeberg, J.; Habuka, M.; Tahmasebpoor, S.; Danielsson, A.; Edlund, K.; et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell Proteom. 2014, 13, 397–406. [Google Scholar] [CrossRef] [Green Version]
  49. Yu, Y.; Fuscoe, J.C.; Zhao, C.; Guo, C.; Jia, M.; Qing, T.; Bannon, D.I.; Lancashire, L.; Bao, W.; Du, T.; et al. A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages. Nat. Commun. 2014, 5, 3230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Yue, F.; Cheng, Y.; Breschi, A.; Vierstra, J.; Wu, W.; Ryba, T.; Sandstrom, R.; Ma, Z.; Davis, C.; Pope, B.D.; et al. A comparative encyclopedia of DNA elements in the mouse genome. Nature 2014, 515, 355–364. [Google Scholar] [CrossRef] [Green Version]
  51. Tovar, A.R.; Ascencio, C.; Torres, N. Soy protein, casein, and zein regulate histidase gene expression by modulating serum glucagon. Am. J. Physiol. Endocrinol. Metab. 2002, 283, E1016–E1022. [Google Scholar] [CrossRef] [Green Version]
  52. Kanamoto, R.; Su, Y.; Pitot, H.C. Effects of glucose, insulin, and cAMP on transcription of the serine dehydratase gene in rat liver. Arch. Biochem. Biophys. 1991, 288, 562–566. [Google Scholar] [CrossRef] [PubMed]
  53. Brosnan, J.T.; Ewart, H.S.; Squires, S.A. Hormonal control of hepatic glutaminase. Adv. Enzyme Regul. 1995, 35, 131–146. [Google Scholar] [CrossRef] [PubMed]
  54. Korenfeld, N.; Finkel, M.; Buchshtab, N.; Bar-Shimon, M.; Charni-Natan, M.; Goldstein, I. Fasting Hormones Synergistically Induce Amino Acid Catabolism Genes to Promote Gluconeogenesis. Cell Mol. Gastroenterol. Hepatol. 2021, 12, 1021–1036. [Google Scholar] [CrossRef] [PubMed]
  55. Schutz, G.; Schmid, W.; Jantzen, M.; Danesch, U.; Gloss, B.; Strahle, U.; Becker, P.; Boshart, M. Molecular basis for the hormonal regulation of the tyrosine aminotransferase and tryptophan oxygenase genes. Ann. N. Y. Acad. Sci. 1986, 478, 93–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Danesch, U.; Gloss, B.; Schmid, W.; Schutz, G.; Schule, R.; Renkawitz, R. Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoid-responsive elements. EMBO J. 1987, 6, 625–630. [Google Scholar] [CrossRef]
  57. Su, Y.; Kanamoto, R.; Ogawa, H.; Pitot, H.C. Regulatory elements for the tissue-specific expression of the rat serine dehydratase-encoding gene. Gene 1992, 120, 301–306. [Google Scholar] [CrossRef]
  58. Oyadomari, S.; Matsuno, F.; Chowdhury, S.; Kimura, T.; Iwase, K.; Araki, E.; Shichiri, M.; Mori, M.; Takiguchi, M. The gene for hepatocyte nuclear factor (HNF)-4alpha is activated by glucocorticoids and glucagon, and repressed by insulin in rat liver. FEBS Lett. 2000, 478, 141–146. [Google Scholar] [CrossRef] [Green Version]
  59. Contreras, A.V.; Rangel-Escareno, C.; Torres, N.; Aleman-Escondrillas, G.; Ortiz, V.; Noriega, L.G.; Torre-Villalvazo, I.; Granados, O.; Velazquez-Villegas, L.A.; Tobon-Cornejo, S.; et al. PPARalpha via HNF4alpha regulates the expression of genes encoding hepatic amino acid catabolizing enzymes to maintain metabolic homeostasis. Genes Nutr. 2015, 10, 452. [Google Scholar] [CrossRef] [Green Version]
  60. Haas, M.J.; Pitot, H.C. Glucocorticoids stimulate CREB binding to a cyclic-AMP response element in the rat serine dehydratase gene. Arch. Biochem. Biophys. 1999, 362, 317–324. [Google Scholar] [CrossRef]
  61. Aleman, G.; Ortiz, V.; Langley, E.; Tovar, A.R.; Torres, N. Regulation by glucagon of the rat histidase gene promoter in cultured rat hepatocytes and human hepatoblastoma cells. Am. J. Physiol. Endocrinol. Metab. 2005, 289, E172–E179. [Google Scholar] [CrossRef]
  62. Velazquez-Villegas, L.A.; Charabati, T.; Contreras, A.V.; Aleman, G.; Torres, N.; Tovar, A.R. PPARalpha Downregulates Hepatic Glutaminase Expression in Mice Fed Diets with Different Protein:Carbohydrate Ratios. J. Nutr. 2016, 146, 1634–1640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Tobon-Cornejo, S.; Vargas-Castillo, A.; Leyva-Martinez, A.; Ortiz, V.; Noriega, L.G.; Velazquez-Villegas, L.A.; Aleman, G.; Furosawa-Carballeda, J.; Torres, N.; Tovar, A.R. PPARalpha/RXRalpha downregulates amino acid catabolism in the liver via interaction with HNF4alpha promoting its proteasomal degradation. Metabolism 2021, 116, 154705. [Google Scholar] [CrossRef]
  64. Jantzen, H.M.; Strahle, U.; Gloss, B.; Stewart, F.; Schmid, W.; Boshart, M.; Miksicek, R.; Schutz, G. Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell 1987, 49, 29–38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Nitsch, D.; Schutz, G. The distal enhancer implicated in the developmental regulation of the tyrosine aminotransferase gene is bound by liver-specific and ubiquitous factors. Mol. Cell Biol. 1993, 13, 4494–4504. [Google Scholar] [CrossRef]
  66. Tovar, A.R.; Becerril, E.; Hernandez-Pando, R.; Lopez, G.; Suryawan, A.; Desantiago, S.; Hutson, S.M.; Torres, N. Localization and expression of BCAT during pregnancy and lactation in the rat mammary gland. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E480–E488. [Google Scholar] [CrossRef]
  67. DeSantiago, S.; Torres, N.; Suryawan, A.; Tovar, A.R.; Hutson, S.M. Regulation of branched-chain amino acid metabolism in the lactating rat. J. Nutr. 1998, 128, 1165–1171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Christowitz, D.; Mattheyse, F.J.; Balinsky, J.B. Dietary and hormonal regulation of urea cycle enzymes in rat liver. Enzyme 1981, 26, 113–121. [Google Scholar] [CrossRef]
  69. Valencia-Sanchez, M.A.; Liu, J.; Hannon, G.J.; Parker, R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes. Dev. 2006, 20, 515–524. [Google Scholar] [CrossRef] [Green Version]
  70. Stark, A.; Brennecke, J.; Russell, R.B.; Cohen, S.M. Identification of Drosophila MicroRNA targets. PLoS Biol. 2003, 1, E60. [Google Scholar] [CrossRef]
  71. Esslinger, S.M.; Schwalb, B.; Helfer, S.; Michalik, K.M.; Witte, H.; Maier, K.C.; Martin, D.; Michalke, B.; Tresch, A.; Cramer, P.; et al. Drosophila miR-277 controls branched-chain amino acid catabolism and affects lifespan. RNA Biol. 2013, 10, 1042–1056. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Mersey, B.D.; Jin, P.; Danner, D.J. Human microRNA (miR29b) expression controls the amount of branched chain alpha-ketoacid dehydrogenase complex in a cell. Hum. Mol. Genet. 2005, 14, 3371–3377. [Google Scholar] [CrossRef] [PubMed]
  73. Sengupta, D.; Cassel, T.; Teng, K.Y.; Aljuhani, M.; Chowdhary, V.K.; Hu, P.; Zhang, X.; Fan, T.W.; Ghoshal, K. Regulation of hepatic glutamine metabolism by miR-122. Mol. Metab. 2020, 34, 174–186. [Google Scholar] [CrossRef] [PubMed]
  74. Still, E.R.; Yuneva, M.O. Hopefully devoted to Q: Targeting glutamine addiction in cancer. Br. J. Cancer 2017, 116, 1375–1381. [Google Scholar] [CrossRef] [Green Version]
  75. Song, P.; Yang, F.; Jin, H.; Wang, X. The regulation of protein translation and its implications for cancer. Signal Transduct. Target. Ther. 2021, 6, 68. [Google Scholar] [CrossRef]
  76. Wu, Y.; Cheng, Z.; Bai, Y.; Ma, X. Epigenetic Mechanisms of Maternal Dietary Protein and Amino Acids Affecting Growth and Development of Offspring. Curr. Protein Pept. Sci. 2019, 20, 727–735. [Google Scholar] [CrossRef] [PubMed]
  77. Clare, C.E.; Brassington, A.H.; Kwong, W.Y.; Sinclair, K.D. One-Carbon Metabolism: Linking Nutritional Biochemistry to Epigenetic Programming of Long-Term Development. Annu. Rev. Anim. Biosci. 2019, 7, 263–287. [Google Scholar] [CrossRef]
  78. Zdzisinska, B.; Zurek, A.; Kandefer-Szerszen, M. Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. Arch. Immunol. Ther. Exp. 2017, 65, 21–36. [Google Scholar] [CrossRef] [Green Version]
  79. Cheng, Z.; Cheung, P.; Kuo, A.J.; Yukl, E.T.; Wilmot, C.M.; Gozani, O.; Patel, D.J. A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36. Genes. Dev. 2014, 28, 1758–1771. [Google Scholar] [CrossRef] [Green Version]
  80. Ito, S.; D’Alessio, A.C.; Taranova, O.V.; Hong, K.; Sowers, L.C.; Zhang, Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466, 1129–1133. [Google Scholar] [CrossRef] [Green Version]
  81. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930–935. [Google Scholar] [CrossRef] [Green Version]
  82. Chalecka, M.; Kazberuk, A.; Palka, J.; Surazynski, A. P5C as an Interface of Proline Interconvertible Amino Acids and Its Role in Regulation of Cell Survival and Apoptosis. Int. J. Mol. Sci. 2021, 22, 11763. [Google Scholar] [CrossRef]
  83. Cyr, A.R.; Domann, F.E. The redox basis of epigenetic modifications: From mechanisms to functional consequences. Antioxid. Redox Signal 2011, 15, 551–589. [Google Scholar] [CrossRef] [Green Version]
  84. Phang, J.M.; Liu, W.; Hancock, C. Bridging epigenetics and metabolism: Role of non-essential amino acids. Epigenetics 2013, 8, 231–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Kilberg, M.S.; Terada, N.; Shan, J. Influence of Amino Acid Metabolism on Embryonic Stem Cell Function and Differentiation. Adv. Nutr. 2016, 7, 780S–789S. [Google Scholar] [CrossRef] [Green Version]
  86. Vanweert, F.; Schrauwen, P.; Phielix, E. Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes. Nutr. Diabetes 2022, 12, 35. [Google Scholar] [CrossRef]
  87. Newsholme, P. Cellular and metabolic mechanisms of nutrient actions in immune function. Eur. J. Clin. Nutr. 2021, 75, 1328–1331. [Google Scholar] [CrossRef] [PubMed]
  88. Kelly, B.; Pearce, E.L. Amino Assets: How Amino Acids Support Immunity. Cell Metab. 2020, 32, 154–175. [Google Scholar] [CrossRef] [PubMed]
  89. Kedia-Mehta, N.; Finlay, D.K. Competition for nutrients and its role in controlling immune responses. Nat. Commun. 2019, 10, 2123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Loftus, R.M.; Finlay, D.K. Immunometabolism: Cellular Metabolism Turns Immune Regulator. J. Biol. Chem. 2016, 291, 1–10. [Google Scholar] [CrossRef] [Green Version]
  91. Calder, P.C. Branched-chain amino acids and immunity. J. Nutr. 2006, 136, 288S–293S. [Google Scholar] [CrossRef] [Green Version]
  92. McGaha, T.L.; Huang, L.; Lemos, H.; Metz, R.; Mautino, M.; Prendergast, G.C.; Mellor, A.L. Amino acid catabolism: A pivotal regulator of innate and adaptive immunity. Immunol. Rev. 2012, 249, 135–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Forouhar, F.; Anderson, J.L.; Mowat, C.G.; Vorobiev, S.M.; Hussain, A.; Abashidze, M.; Bruckmann, C.; Thackray, S.J.; Seetharaman, J.; Tucker, T.; et al. Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 2007, 104, 473–478. [Google Scholar] [CrossRef] [PubMed]
  94. Rafice, S.A.; Chauhan, N.; Efimov, I.; Basran, J.; Raven, E.L. Oxidation of L-tryptophan in biology: A comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem. Soc. Trans. 2009, 37, 408–412. [Google Scholar] [CrossRef] [Green Version]
  95. Kanai, M.; Funakoshi, H.; Takahashi, H.; Hayakawa, T.; Mizuno, S.; Matsumoto, K.; Nakamura, T. Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol. Brain 2009, 2, 8. [Google Scholar] [CrossRef] [Green Version]
  96. Herr, N.; Bode, C.; Duerschmied, D. The Effects of Serotonin in Immune Cells. Front. Cardiovasc. Med. 2017, 4, 48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolusic, E.; Frederick, R.; De Plaen, E.; Uyttenhove, C.; Wouters, J.; Masereel, B.; et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 2012, 109, 2497–2502. [Google Scholar] [CrossRef]
  98. Cervenka, I.; Agudelo, L.Z.; Ruas, J.L. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science 2017, 357, eaaf9794. [Google Scholar] [CrossRef] [Green Version]
  99. Currier, A.R.; Ziegler, M.H.; Riley, M.M.; Babcock, T.A.; Telbis, V.P.; Carlin, J.M. Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently. J. Interferon Cytokine Res. 2000, 20, 369–376. [Google Scholar] [CrossRef]
  100. Taylor, M.W.; Feng, G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5, 2516–2522. [Google Scholar] [CrossRef]
  101. Mezrich, J.D.; Fechner, J.H.; Zhang, X.; Johnson, B.P.; Burlingham, W.J.; Bradfield, C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010, 185, 3190–3198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Lee, J.; Ryu, H.; Ferrante, R.J.; Morris, S.M., Jr.; Ratan, R.R. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc. Natl. Acad. Sci. USA 2003, 100, 4843–4848. [Google Scholar] [CrossRef] [PubMed]
  103. Rath, M.; Muller, I.; Kropf, P.; Closs, E.I.; Munder, M. Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages. Front. Immunol. 2014, 5, 532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Stout, R.D.; Suttles, J. Functional plasticity of macrophages: Reversible adaptation to changing microenvironments. J. Leukoc. Biol. 2004, 76, 509–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Gordon, S.; Martinez, F.O. Alternative activation of macrophages: Mechanism and functions. Immunity 2010, 32, 593–604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Bogdan, C.; Rollinghoff, M.; Diefenbach, A. The role of nitric oxide in innate immunity. Immunol. Rev. 2000, 173, 17–26. [Google Scholar] [CrossRef]
  107. Kepka-Lenhart, D.; Mistry, S.K.; Wu, G.; Morris, S.M., Jr. Arginase I: A limiting factor for nitric oxide and polyamine synthesis by activated macrophages? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279, R2237–R2242. [Google Scholar] [CrossRef] [Green Version]
  108. Bronte, V.; Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005, 5, 641–654. [Google Scholar] [CrossRef]
  109. Zhang, D.; Tang, Z.; Huang, H.; Zhou, G.; Cui, C.; Weng, Y.; Liu, W.; Kim, S.; Lee, S.; Perez-Neut, M.; et al. Metabolic regulation of gene expression by histone lactylation. Nature 2019, 574, 575–580. [Google Scholar] [CrossRef]
  110. Grohmann, U.; Bronte, V. Control of immune response by amino acid metabolism. Immunol. Rev. 2010, 236, 243–264. [Google Scholar] [CrossRef]
  111. Li, P.; Yin, Y.L.; Li, D.; Kim, S.W.; Wu, G. Amino acids and immune function. Br. J. Nutr. 2007, 98, 237–252. [Google Scholar] [CrossRef] [Green Version]
  112. Guevara-Cruz, M.; Vargas-Morales, J.M.; Mendez-Garcia, A.L.; Lopez-Barradas, A.M.; Granados-Portillo, O.; Ordaz-Nava, G.; Rocha-Viggiano, A.K.; Gutierrez-Leyte, C.A.; Medina-Cerda, E.; Rosado, J.L.; et al. Amino acid profiles of young adults differ by sex, body mass index and insulin resistance. Nutr. Metab. Cardiovasc. Dis. 2018, 28, 393–401. [Google Scholar] [CrossRef]
  113. Medina-Vera, I.; Sanchez-Tapia, M.; Noriega-Lopez, L.; Granados-Portillo, O.; Guevara-Cruz, M.; Flores-Lopez, A.; Avila-Nava, A.; Fernandez, M.L.; Tovar, A.R.; Torres, N. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019, 45, 122–131. [Google Scholar] [CrossRef]
  114. Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D.; Fox, C.S.; Jacques, P.F.; Fernandez, C.; et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011, 17, 448–453. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Neinast, M.; Murashige, D.; Arany, Z. Branched Chain Amino Acids. Annu. Rev. Physiol. 2019, 81, 139–164. [Google Scholar] [CrossRef] [PubMed]
  116. Estrada-Alcalde, I.; Tenorio-Guzman, M.R.; Tovar, A.R.; Salinas-Rubio, D.; Torre-Villalvazo, I.; Torres, N.; Noriega, L.G. Metabolic Fate of Branched-Chain Amino Acids During Adipogenesis, in Adipocytes From Obese Mice and C2C12 Myotubes. J. Cell Biochem. 2017, 118, 808–818. [Google Scholar] [CrossRef]
  117. Lackey, D.E.; Lynch, C.J.; Olson, K.C.; Mostaedi, R.; Ali, M.; Smith, W.H.; Karpe, F.; Humphreys, S.; Bedinger, D.H.; Dunn, T.N.; et al. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am. J. Physiol. Endocrinol. Metab. 2013, 304, E1175–E1187. [Google Scholar] [CrossRef] [Green Version]
  118. Salinas-Rubio, D.; Tovar, A.R.; Torre-Villalvazo, I.; Granados-Portillo, O.; Torres, N.; Pedraza-Chaverri, J.; Noriega, L.G. Interaction between leucine and palmitate catabolism in 3T3-L1 adipocytes and primary adipocytes from control and obese rats. J. Nutr. Biochem. 2018, 59, 29–36. [Google Scholar] [CrossRef] [PubMed]
  119. She, P.; Van Horn, C.; Reid, T.; Hutson, S.M.; Cooney, R.N.; Lynch, C.J. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E1552–E1563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  120. Zoncu, R.; Bar-Peled, L.; Efeyan, A.; Wang, S.; Sancak, Y.; Sabatini, D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 2011, 334, 678–683. [Google Scholar] [CrossRef] [Green Version]
  121. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  122. Newgard, C.B.; An, J.; Bain, J.R.; Muehlbauer, M.J.; Stevens, R.D.; Lien, L.F.; Haqq, A.M.; Shah, S.H.; Arlotto, M.; Slentz, C.A.; et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009, 9, 311–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Green, C.R.; Wallace, M.; Divakaruni, A.S.; Phillips, S.A.; Murphy, A.N.; Ciaraldi, T.P.; Metallo, C.M. Branched-chain amino acid catabolism fuels adipocyte differentiation and lipogenesis. Nat. Chem. Biol. 2016, 12, 15–21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Halama, A.; Horsch, M.; Kastenmuller, G.; Moller, G.; Kumar, P.; Prehn, C.; Laumen, H.; Hauner, H.; Hrabe de Angelis, M.; Beckers, J.; et al. Metabolic switch during adipogenesis: From branched chain amino acid catabolism to lipid synthesis. Arch. Biochem. Biophys. 2016, 589, 93–107. [Google Scholar] [CrossRef] [Green Version]
  125. Hong, S.; Zhou, W.; Fang, B.; Lu, W.; Loro, E.; Damle, M.; Ding, G.; Jager, J.; Zhang, S.; Zhang, Y.; et al. Dissociation of muscle insulin sensitivity from exercise endurance in mice by HDAC3 depletion. Nat. Med. 2017, 23, 223–234. [Google Scholar] [CrossRef] [Green Version]
  126. Lerin, C.; Goldfine, A.B.; Boes, T.; Liu, M.; Kasif, S.; Dreyfuss, J.M.; De Sousa-Coelho, A.L.; Daher, G.; Manoli, I.; Sysol, J.R.; et al. Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism. Mol. Metab. 2016, 5, 926–936. [Google Scholar] [CrossRef]
  127. Muoio, D.M. Metabolic inflexibility: When mitochondrial indecision leads to metabolic gridlock. Cell 2014, 159, 1253–1262. [Google Scholar] [CrossRef] [Green Version]
  128. Chandel, N.S. Amino Acid Metabolism. Cold Spring Harb. Perspect. Biol. 2021, 13, a040584. [Google Scholar] [CrossRef]
  129. Oxenkrug, G.F. Genetic and hormonal regulation of tryptophan kynurenine metabolism: Implications for vascular cognitive impairment, major depressive disorder, and aging. Ann. N. Y. Acad. Sci. 2007, 1122, 35–49. [Google Scholar] [CrossRef]
  130. Schwarcz, R. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 2004, 4, 12–17. [Google Scholar] [CrossRef]
  131. Chen, T.; Zheng, X.; Ma, X.; Bao, Y.; Ni, Y.; Hu, C.; Rajani, C.; Huang, F.; Zhao, A.; Jia, W.; et al. Tryptophan Predicts the Risk for Future Type 2 Diabetes. PLoS ONE 2016, 11, e0162192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  132. Breum, L.; Rasmussen, M.H.; Hilsted, J.; Fernstrom, J.D. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. Am. J. Clin. Nutr. 2003, 77, 1112–1118. [Google Scholar] [CrossRef] [Green Version]
  133. Muzik, O.; Burghardt, P.; Yi, Z.; Kumar, A.; Seyoum, B. Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. Biochem. Biophys. Res. Commun. 2017, 488, 29–32. [Google Scholar] [CrossRef] [PubMed]
  134. Oxenkrug, G.; van der Hart, M.; Summergrad, P. Elevated anthranilic acid plasma concentrations in type 1 but not type 2 diabetes mellitus. Integr. Mol. Med. 2015, 2, 365–368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Kotake, Y.; Ueda, T.; Mori, T.; Igaki, S.; Hattori, M. Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid (XA). Acta Vitaminol. Enzymol. 1975, 29, 236–239. [Google Scholar] [PubMed]
  136. Lin, H.V.; Efanov, A.M.; Fang, X.; Beavers, L.S.; Wang, X.; Wang, J.; Gonzalez Valcarcel, I.C.; Ma, T. GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism. PLoS ONE 2016, 11, e0157298. [Google Scholar] [CrossRef] [Green Version]
  137. Chouchani, E.T.; Kazak, L.; Spiegelman, B.M. New Advances in Adaptive Thermogenesis: UCP1 and Beyond. Cell Metab. 2019, 29, 27–37. [Google Scholar] [CrossRef]
  138. Nicholls, D.G. The hunt for the molecular mechanism of brown fat thermogenesis. Biochimie 2017, 134, 9–18. [Google Scholar] [CrossRef]
  139. Wang, Z.; Wang, Q.A.; Liu, Y.; Jiang, L. Energy metabolism in brown adipose tissue. FEBS J. 2021, 288, 3647–3662. [Google Scholar] [CrossRef]
  140. Yoneshiro, T.; Wang, Q.; Tajima, K.; Matsushita, M.; Maki, H.; Igarashi, K.; Dai, Z.; White, P.J.; McGarrah, R.W.; Ilkayeva, O.R.; et al. BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. Nature 2019, 572, 614–619. [Google Scholar] [CrossRef]
Nutrients 15 03378 g001 550
Figure 1. Amino acid catabolism in the liver. (A) Amino acids are used for protein synthesis and the generation of nitrogenous compounds. In the case of an excess in the consumption of amino acids, they are oxidized and utilized as energy fuel. (B) Amino acid catabolism in the liver involves several degrading processes, including the removal and transfer of the amino group, deamination, and transamination. Some amino acids undergo several degrading processes, like decarboxylation and dehydrogenation. The amino group enters the urea cycle for excretion. The carbon skeleton can be used for glucose formation by gluconeogenesis or for ATP production in the Krebs cycle, followed by the respiratory chain.
Figure 1. Amino acid catabolism in the liver. (A) Amino acids are used for protein synthesis and the generation of nitrogenous compounds. In the case of an excess in the consumption of amino acids, they are oxidized and utilized as energy fuel. (B) Amino acid catabolism in the liver involves several degrading processes, including the removal and transfer of the amino group, deamination, and transamination. Some amino acids undergo several degrading processes, like decarboxylation and dehydrogenation. The amino group enters the urea cycle for excretion. The carbon skeleton can be used for glucose formation by gluconeogenesis or for ATP production in the Krebs cycle, followed by the respiratory chain.
Nutrients 15 03378 g001
Nutrients 15 03378 g004 550
Figure 4. Influence of amino acid catabolism in physiopathological processes. (A) Individual amino acids and their metabolites can affect immune responses. In the intestinal epithelium, short-chain fatty acids (SCFAs) produced by bacteria from dietary carbohydrates and/or amino acids downregulate the expression of the tryptophan catabolism enzyme indoleamine 2,3-dioxygenase (IDO-1). In contrast, lipopolysaccharide (LPS) and TNF-α (tumor necrosis factor-a) generated by Gram-negative bacteria induce its expression. Tryptophan (Trp) catabolism in the gut can influence the amino acid pool. (B) Transamination of the branched-chain amino acids (BCAA) by BCAT2 is extrahepatic for branched-chain alpha-keto acids (BCKA) production. The liver mitochondrial BCKDH complex catalyzes the oxidative decarboxylation of BCKA. (C) Increased levels of BCAA are found in obesity and type 2 diabetes. BCAA metabolism generates some intermediates of tricarboxylic acid (TCA), leading to an increase in fatty acid oxidation that could decrease glucose utilization in the skeletal muscle. mTORC1 activation activates lipogenesis and adipogenesis and inhibits autophagy and insulin signaling by inactivating the insulin receptor substrate 1 (IRS1) in the white adipose tissue. Decreased Trp levels due to an increase in the expression of enzymes (IDO1, IDO2, and TDO2) of the Trp-Kynurenine pathway are associated with decreased insulin secretion and insulin resistance. (D) Amino acid catabolism also plays a role in the induction of thermogenesis in the brown adipose tissue (BAT). BAT mitochondria express BCAT2 and BCKDH and can use BCAA as an energy source to increase thermogenesis. BCAA are transported into the mitochondria by the SLC25A44 transporter to generate reduced intermediates that pump protons in the respiratory chain to produce heat through uncoupling protein 1 (UCP1).
Figure 4. Influence of amino acid catabolism in physiopathological processes. (A) Individual amino acids and their metabolites can affect immune responses. In the intestinal epithelium, short-chain fatty acids (SCFAs) produced by bacteria from dietary carbohydrates and/or amino acids downregulate the expression of the tryptophan catabolism enzyme indoleamine 2,3-dioxygenase (IDO-1). In contrast, lipopolysaccharide (LPS) and TNF-α (tumor necrosis factor-a) generated by Gram-negative bacteria induce its expression. Tryptophan (Trp) catabolism in the gut can influence the amino acid pool. (B) Transamination of the branched-chain amino acids (BCAA) by BCAT2 is extrahepatic for branched-chain alpha-keto acids (BCKA) production. The liver mitochondrial BCKDH complex catalyzes the oxidative decarboxylation of BCKA. (C) Increased levels of BCAA are found in obesity and type 2 diabetes. BCAA metabolism generates some intermediates of tricarboxylic acid (TCA), leading to an increase in fatty acid oxidation that could decrease glucose utilization in the skeletal muscle. mTORC1 activation activates lipogenesis and adipogenesis and inhibits autophagy and insulin signaling by inactivating the insulin receptor substrate 1 (IRS1) in the white adipose tissue. Decreased Trp levels due to an increase in the expression of enzymes (IDO1, IDO2, and TDO2) of the Trp-Kynurenine pathway are associated with decreased insulin secretion and insulin resistance. (D) Amino acid catabolism also plays a role in the induction of thermogenesis in the brown adipose tissue (BAT). BAT mitochondria express BCAT2 and BCKDH and can use BCAA as an energy source to increase thermogenesis. BCAA are transported into the mitochondria by the SLC25A44 transporter to generate reduced intermediates that pump protons in the respiratory chain to produce heat through uncoupling protein 1 (UCP1).
Nutrients 15 03378 g004
Table
Table 1. Amino acid degrading enzymes and main organ locations in humans, rats and mice.
Table 1. Amino acid degrading enzymes and main organ locations in humans, rats and mice.
Amino Acid
(1-Letter)		AADENameAADETissue Expression Humans [48]Tissue Expression Rat [49]Tissue Expression Mouse [50]
Alanine (A)Glutamic pyruvate transaminaseGptLiver, Kidney, fat, colon, duodenum small intestine, stomachLiver, lung muscle, thymus, uterus Liver, duodenum, large intestine, subcutaneous fat pad, stomach
Arginine (R)Arginase 1Arg1Liver, skyn, bone marrow Liver, lung, testes, uterus Liver, lung, ovary
Asparagine (N)Asparaginase AspgLiver, kidney, heart, ovary, colon, sky, stomach, lung Liver, kidney, lung. Adrenal, testes Liver, kidney, mammary gland, colon, large intestine
Aspartic acid (D)glutamic-oxaloacetic transaminase 1Got1Heart, liver, kidney, brain, duodenum, colon, small intestine Heart, muscle, brain, liver, lung Heart, liver, kidney, cerebellum, cortex
Cysteine (C)Cysteine dioxygenase 1Cdo1Liver, fat, placenta, testis, brain, lung Liver, thymus, adrenal, lung Liver, genital fat, mammary gland, subcutaneous fat pad
Glutamic acid (E)Glutamate dehydrogenase 1 Glud1Liver, kidney, prostate, brain, small intestine, stomach, adrenal (16)Liver, kidney, brain, uterus, muscle, heart Liver, kidney, small intestine, adrenal
Glutamine (Q)GlutaminaseGlsLiver, kidney, small intestine, brain, duodenum, lung Kidney, brain, adrenal, lung, muscle, testes, thymus, liverCNS E18, Cortex, frontal lobe, cerebelum, thymus
Glycine (G)Serine hydroximethyl transferase 1Shmt1Kidney, liver, fat, duodenum, small intestine, esophagus, thyroid Kidney, liver, adrenal, testes, thymus Liver, kidney, placenta, testis
Histidine (H)Histidine ammonia lyaseHalLiver, skin, bone marrow, appendix, spleen.Liver, lung, testes, uterus.Liver, genital fat pad, placenta
Lysine (K)Glutaryl-CoA dehydrogenaseGcdhLiver, kidney, ovary, fat, heart Kidney, liver, adrenal, lung, muscleLiver, kidney, adrenal, heart
Methionine (M)Methionine adenosyl transferaseMat1aLiver, pancreas, ovary, skin, testisLiver, lung, uterus, adrenalLiver
Phenylalanine (F)Phenylalanine hidroxylasePahLiver, kidney, gall bladder Liver, kidney, lung, testes, uterus Kidney, liver
Proline (P)Proline dehydrogenaseProdhSmall intestine, skin, lung, duodenum, brain, kidney Liver, kidney, heart, thymus, brain Kidney, liver, large intestine, small intestine, genital, duodenum
Serine (S)Serine dehydrataseSdsLiver, stomach, brain Liver, kidney, testes Liver, heart
Threonine (T)Serine dehydratase likesdslKidney, liver, thyroid, adrenal, colon duodenum Testes, liver, kidney, brain, uterusAdrenal, duodenum, ovary, colon
Tryptophan (W)Tryptophan 2,3-dioxygenaseTdo2Liver, appendix, urinary bladder, small intestine Liver, lung, uterus Liver, placenta
Aminocarboxymuconate semialdehyde decarboxylaseAcmsdKidney, liver, gall bladder Kidney, liverKidney, liver
Tyrosine (Y)Tyrosine aminotransferaseTatLiver Liver, kidney, colon, large intestine Liver, lung, uterus, adrenal
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Torres, N.; Tobón-Cornejo, S.; Velazquez-Villegas, L.A.; Noriega, L.G.; Alemán-Escondrillas, G.; Tovar, A.R. Amino Acid Catabolism: An Overlooked Area of Metabolism. Nutrients 2023, 15, 3378. https://doi.org/10.3390/nu15153378

AMA Style

Torres N, Tobón-Cornejo S, Velazquez-Villegas LA, Noriega LG, Alemán-Escondrillas G, Tovar AR. Amino Acid Catabolism: An Overlooked Area of Metabolism. Nutrients. 2023; 15(15):3378. https://doi.org/10.3390/nu15153378

Chicago/Turabian Style

Torres, Nimbe, Sandra Tobón-Cornejo, Laura A. Velazquez-Villegas, Lilia G. Noriega, Gabriela Alemán-Escondrillas, and Armando R. Tovar. 2023. "Amino Acid Catabolism: An Overlooked Area of Metabolism" Nutrients 15, no. 15: 3378. https://doi.org/10.3390/nu15153378

APA Style

Torres, N., Tobón-Cornejo, S., Velazquez-Villegas, L. A., Noriega, L. G., Alemán-Escondrillas, G., & Tovar, A. R. (2023). Amino Acid Catabolism: An Overlooked Area of Metabolism. Nutrients, 15(15), 3378. https://doi.org/10.3390/nu15153378

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop